Carmen Scheibenbogen

Professor Doctor Carmen Scheibenbogen is an Internal Medicine physician, ME/CFS doctor and the Professor for Immunology and Deputy Chair, Institute of Medical Immunology, at the University Hospital Charité in Berlin, Germany. Her research focuses on the role of Epstein-Barr virus (EBV), particularly the characterization of EBV specific B cell and T cell response and the enhanced antibody response against EBV peptides in myalgic encephalomyelitis (ME) versus healthy controls.

EUROMENE
Professor Scheibenbogen is the Leader of the Biomarkers Working Group of EUROMENE, a European Union, COST Action CA15111, not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Diagnostic test
Professor Scheibenbogen helped create the CellTrend Diagnostic Test which may help identify a subset of 20-30% of all patients with ME/CFS. These patients have elevated levels of three auto-antibodies, i.e., against the b2-adrenergic receptor, against the muscarinic cholinergic receptor 3 (M3) and against the muscarinic cholinergic receptor 4 (M4).

Awards

 * 2016 Ramsay Award Program grant recipient, sponsored by the Solve ME/CFS Initiative for Autoimmune Signature in myalgic encephalomyelitis/chronic fatigue syndrome. This grant was shared with Madlen Löbel, Charité Universitätsmedizin Berlin.
 * 2017 Ramsay Award Program grant was awarded to a team comprised of Dr. Carmen Scheibenbogen and Dr. Franziska Sotzny of Charité Universitätsmedizin Berlin, sponsored by the Solve ME/CFS Initiative for researching immunometabolism of T cells and monocytes in ME/CFS.

Notable studies

 * 2014, Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome - (Full Text)
 * 2015, Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome - (Full Text)
 * 2015, Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome - (Full Text)
 * 2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome - (Full Text)
 * 2017, Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray - (Full Text)
 * 2017, The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE - (Full Text)
 * 2018, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease - (Full Text)
 * 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME - (Full Text)
 * 2018, The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome - (Full Text)
 * 2018, Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review - (Full text)
 * 2018, Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - (Full text)
 * 2019, Myalgic encephalomyelitis/chronic fatigue Syndrome (ME/CFS): Investigating care practices pointed out to disparities in diagnosis and treatment across European Union - (Full text)
 * 2020, IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS - (Full text)
 * 2020, Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - (Full text)
 * 2020, Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology - (Full text)
 * 2020, Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome - (Full text)
 * 2020, Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset - (Full text)
 * 2020, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption - (Full text)
 * 2021, The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies - (Full text)
 * 2020, A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors - (Full text)
 * 2021, Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - (Full text)
 * 2021, European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe - (Full text)
 * 2021, Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - (Full text)
 * 2021, Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study - (Full text)
 * 2021, Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Germany - (Full text)

Clinic location

 * Charité University Medicine, Berlin, Germany

Talks and interviews

 * 2021, Autoimmune ME/CFS Treatment Options - IACFS/ME Conference
 * 2018, Talk "Chronic Fatigue Syndrome" for General Practitioners
 * 2014, Speaker at the 9th Invest in ME International ME Conference DVD available

Online presence

 * Researchgate.net
 * PubMed
 * Institute for Medical Immunology
 * Charité Fatigue Centrum

Learn more

 * Carmen Schiebenbogen - Solve ME/CFS Initiative
 * Carmen Schiebenbogen page 2 - Solve ME/CFS Initiative
 * Curriculum Vitae for EUROMENE